Graphene oxide bulk material reinforced by heterophase platelets with multiscale interface crosslinking.

Graphene oxide (GO) and reduced GO possess robust mechanical, electrical and chemical properties. Their nanocomposites have been extensively explored for applications in diverse fields. However, due to the high flexibility and weak interlayer interactions of GO nanosheets, the flexural mechanical properties of GO-based composites, especially in bulk materials, are largely constrained, which hinders their performance in practical applications. Here, inspired by the amorphous/crystalline feature of the heterophase within nacreous platelets, we present a centimetre-sized, GO-based bulk material consisting of building blocks of GO and amorphous/crystalline leaf-like MnO2 hexagon nanosheets adhered together with polymer-based crosslinkers. These building blocks are stacked and hot-pressed with further crosslinking between the layers to form a GO/MnO2-based layered (GML) bulk material. The resultant GML bulk material exhibits a flexural strength of 231.2 MPa. Moreover, the material exhibits sufficient fracture toughness and strong impact resistance while being light in weight. Experimental and numerical analyses indicate that the ordered heterophase structure and synergetic crosslinking interactions across multiscale interfaces lead to the superior mechanical properties of the material. These results are expected to provide insights into the design of structural materials and potential applications of high-performance GO-based bulk materials in aerospace, biomedicine and electronics.

Synthetic hydrogel nanoparticles for sepsis therapy.

Sepsis is a life-threatening condition caused by the extreme release of inflammatory mediators into the blood in response to infection (e.g., bacterial infection, COVID-19), resulting in the dysfunction of multiple organs. Currently, there is no direct treatment for sepsis. Here we report an abiotic hydrogel nanoparticle (HNP) as a potential therapeutic agent for late-stage sepsis. The HNP captures and neutralizes all variants of histones, a major inflammatory mediator released during sepsis. The highly optimized HNP has high capacity and long-term circulation capability for the selective sequestration and neutralization of histones. Intravenous injection of the HNP protects mice against a lethal dose of histones through the inhibition of platelet aggregation and migration into the lungs. In vivo administration in murine sepsis model mice results in near complete survival. These results establish the potential for synthetic, nonbiological polymer hydrogel sequestrants as a new intervention strategy for sepsis therapy and adds to our understanding of the importance of histones to this condition.